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aDDeNDUM
Neurofibromatosis type 1 (NF1) is caused by loss of a negative 
regulator of Ras oncoproteins. Unknown 
genetic modifiers have been implicated 
in NF1’s characteristic variability. 
Drosophila melanogaster dNf1 
phenotypes include cognitive deficits and 
reduced growth, both of which resemble 
human symptoms. We recently reported 
results of a screen for dominant modifiers 
of dNf1 growth. Suppressors include the 
dAlk tyrosine kinase and its activating 
ligand, two other genes involved in 
Ras/ERK signal transduction, the 
synaptic scaffold Dap160 and the 
CCKLR-17D1 drosulfakinin receptor. 
Additional modifiers include several 
genes involved in cAMP/PKA signaling. 
Providing mechanistic insights, dAlk, 
jeb, and CCKLR-17D1 also suppress a 
dNf1 synaptic overgrowth defect, and 
increasing cAMP/PKA signaling in the 
neuroendocrine ring gland rescued the 
dNf1 growth deficiency. Finally, among 
the several suppressors identified in our 
screen, we specifically implicate ALK as 
a potential therapeutic target by showing 
that NF1-regulated ALK/RAS/ERK 
signaling is conserved in human cells.
RASopathies are a group of clinically 
related genetic disorders caused by defects 
in RAS/ERK signal transduction.1 NF1 is 
among the most common members of this 
group, affecting an estimated 1 in 3000 
individuals in all ethnic groups. High 
degrees of variability and unpredictability 
are among the hallmarks of NF1. Patients 
are predisposed to developing a variety of 
symptoms, the most common of which 
include benign but potentially highly 
disfiguring peripheral nerve associated 
tumors, termed neurofibromas. Malignant 
tumors, including peripheral nerve sheath 
tumors, are also strongly associated with 
NF1. Frequent non-tumor symptoms 
include skeletal and skin pigmentation 
abnormalities, reduced overall growth, 
and cognitive deficits, the latter seen in 
50–70% of children with NF1.2
NF1 is caused by mutations that 
impact the function(s) of neurofibromin, 
a large and evolutionarily conserved 
GTPase Activating Protein (GAP) for 
Ras oncoproteins.3 Neurofibromin and 
other RasGAPs accelerate the conversion 
of active Ras-GTP into inactive Ras-
GDP by stimulating the low intrinsic rate 
of Ras-GTP hydrolysis. While excessive 
Ras signaling upon loss of neurofibromin 
is undoubtedly a major cause of NF1 
defects, evidence has also been presented 
that neurofibromin, in Ras-dependent or 
Ras-independent ways, acts as a positive 
mediator of adenylyl cyclase activity.4-6
To shed light on the functions of 
neurofibromin, the molecular pathways 
involved in NF1 defects and the identity 
of modifier genes implicated in the 
characteristic variability of this disease,7 
we previously generated loss-of-function 
mutants of a highly conserved Drosophila 
melanogaster dNf1 ortholog. Homozygous 
dNf1 null mutants are viable and fertile, 
but show a 15–20% reduction in linear 
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dimensions during all post-embryonic 
developmental stages.8 Mutants also 
have a reduced escape response (taking 
flight upon release), lack a neuropeptide-
elicited rectifying K+-current defect at 
the neuromuscular junction (NMJ), 
and exhibit circadian arrhythmicity, 
olfactory associative learning, and 
memory deficits.8-11 Remarkably, all 
defects but the circadian arrhythmicity 
are not particularly sensitive to genetic 
manipulation of Ras signaling but are 
suppressed by increasing cAMP/PKA 
pathway signaling or mimicked by 
decreasing signaling through the cAMP/
PKA pathway.
While there is little doubt that loss of 
NF1 affects cAMP/PKA signaling, we and 
another group have reached contradictory 
conclusions about the mechanism(s) 
involved. Yi Zhong and colleagues 
reported that a C-terminal segment of 
human neurofibromin (that does not 
include the RasGAP catalytic domain) is 
sufficient for NF1/Galpha(S)-dependent 
neurotransmitter stimulated adenylyl 
cyclase activation and rescue of the dNf1 
growth defect.4 In contrast, we found that 
expression of a functional dNf1 RasGAP 
catalytic domain is both necessary and 
sufficient to restore the cAMP/PKA-
sensitive growth deficiency. Moreover, 
dNf1 expression during the larval growth 
phase is largely restricted to neurons, and 
expression of an unrelated Drosophila 
RasGAP in these cells sufficed to restore 
normal growth. Finally, although multiple 
Ras signaling mutants did not dominantly 
modify dNf1 systemic growth, these 
mutants also did not reduce the elevated 
phospho-ERK level in dNf1 larval brain.12
Our conclusion that neuronal Ras/
ERK over-activation is the root cause of the 
cAMP/PKA-sensitive dNf1 growth defect 
received further support from subsequent 
work. Neuronal overexpression of the dAlk 
receptor tyrosine kinase or of its activating 
ligand jelly belly ( jeb) phenocopied dNf1 
growth and learning defects, while 
genetic or pharmacological attenuation 
of Jeb/dAlk signaling suppressed both 
phenotypes. Specifically implicating 
Ras-stimulated ERK over-activation, this 
study also found that neuronal expression 
of a constitutively active ERK mutant 
phenocopied the dNf1 growth defect.13
To shed further light on dNf1’s role in 
organismal growth and on the mechanistic 
links between dNf1 and cAMP/PKA 
signaling, we recently reported results of 
an unbiased genetic screen for dominant 
modifiers of the dNf1 growth defect.14 
Our screen analyzed 486 isogenic first 
and second chromosome deficiencies, 
each typically uncovering between 1 and 
25 genes. The deficiencies, which together 
uncover close to 80% of first and second 
chromosome genes, were crossed into the 
dNf1 null background, and modifying 
deficiencies were identified by measuring 
the length of pupal cases (Fig. 1). After 
eliminating deficiencies that also affect 
the size of wild-type pupae, responsible 
modifier genes were identified in crosses 
with available alleles, or by neuronal- 
or glial-specific RNAi knockdown of 
candidate genes.
Validating the screen, we identified dAlk, 
its activating ligand jelly belly ( jeb), and 
the dunce (dnc) cAMP phosphodiesterase 
as dominant suppressors. All three genes 
had been identified previously as dNf1 
phenotypic suppressors.11,13 Earlier work 
had also established that heat shock-
induced expression of a constitutively 
active murine PKA* catalytic subunit 
transgene normalized dNf1 size,8 whereas 
others found reduced brain adenylyl 
Figure  1. a screen for dominant dNf1 growth defect modifiers. dNf1 mutants are smaller than 
wild-type flies. to identify modifiers of this phenotype, 486 isogenic deficiencies uncovering 
~80% of first and second chromosome genes were crossed into a dNf1 null mutant background, 
and the length of the resulting pupal cases measured. Confounding factors include that size is a 
sexually dimorphic phenotype, with males being smaller than females, and that systemic growth 
is a multifaceted process influenced by environmental factors, such as food availability and 
temperature. employing strategies to minimize these and other confounding factors, and after 
eliminating those deficiencies with non-specific effects on growth, candidate dNf1 modifying 
deficiencies were examined by testing alleles or shrNai lines to identify the responsible modifier 
genes.
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cyclase activity upon loss of Drosophila 
or murine Nf1.15 Thus, we were not 
surprised to identify the PKA-C1 catalytic 
subunit as an enhancer, and the PKA-
R2 regulatory subunit as a yet to be 
fully confirmed candidate suppressor. 
Providing mechanistic insights, follow-up 
experiments indicated that growth 
regulation by dNf1 and cAMP/PKA likely 
involves different cells. First, arguing 
against the idea that PKA suppresses 
dNf1 defects by attenuating RAS/ERK 
signaling, we found that widespread or 
tissue-specific transgenic PKA* expression 
does not reduce the elevated phospho-ERK 
level in dNf1 larval brain. Second, whereas 
only relatively widespread neuronal dNf1 
re-expression restored the mutant growth 
defect,12 in the current study, genetic 
manipulations that increased cAMP/
PKA signaling in specific parts of the 
larval ring gland (a neuroendocrine gland 
analogous to the mammalian pituitary) 
were sufficient to restore dNf1 growth. 
By contrast, expressing dNf1 in the ring 
gland or widespread neuronal expression 
of a dncRNAi transgene outside of the ring 
gland had no effect.14 These results argue 
that dNf1 controls Drosophila growth by 
non-cell-autonomously affecting cAMP/
PKA signaling in the ring gland (Fig. 2). 
Whether a similar non-cell-autonomous 
neuroendocrine mechanism underlies 
the reduced growth of patients with 
NF1 or other RASopathies remains to be 
established.
Our screen also identified several dNf1 
growth defect suppressors with synaptic 
functions. Examples include the cAMP-
coupled neuronal drosulfakinin receptor 
CCKLR-17D1, a positive regulator of 
synaptic growth, and dynamin-associated 
protein 160 (Dap160), an intersectin-
related scaffold implicated in synaptic 
vesicle exocytosis and neuroblast 
proliferation. Because recent work 
identified a novel dNf1 NMJ overgrowth 
phenotype,16 we tested whether suppressors 
identified in our screen also modified the 
NMJ defect. Suggesting a mechanistic 
link between both phenotypes, loss-of-
function dAlk, Jeb, and CCKLR-D1 alleles 
reduced the number of NMJ synaptic 
boutons.14
Studies in C. elegans and Drosophila 
had previously revealed roles for ALK 
orthologs in synapse formation and 
neuronal differentiation. Thus, work 
in C. elegans suggested that the F-box 
protein FSN-1 and the RING finger 
protein RPM-1 form a ubiquitin ligase 
complex that controls synapse stability 
by targeting ALK ortholog T10H9.2/
SCD-2.17 In Drosophila, Jeb and dAlk are 
both enriched at synapses,18 and function 
to control neurotransmission strength 
and synaptic architecture.19 Based on our 
results, one might speculate that dAlk 
controls synaptic growth by activating 
a dNf1-regulated Ras/ERK signal. 
However, reconciling our data with these 
other results is less than straightforward, 
since dNf1 is primarily expressed in 
neurons and plays its growth-related 
role in these cells (i.e., presynaptically),14 
whereas others concluded that NMJ 
differentiation involves the activation 
of postsynaptic (i.e., muscle expressed) 
dAlk by presynaptically released Jeb.19 
Although we can only speculate at this 
point, one potential explanation is that 
the growth-related role of Jeb, dAlk, and 
dNf1 involves aberrant synaptogenesis 
between neurons, rather than at the 
NMJ. It is worth noting in this respect 
that murine neurofibromin has been 
implicated in synaptic differentiation,20 
and that a recent ultrastructural study 
found reduced curvature at concave 
synapses in the hippocampus of 
Nf1+/− mice.21
Loss of dAlk or Jeb dominantly 
suppressed dNf1 growth, associative 
learning, and neuronal ERK over-
activation phenotypes, which, together 
with other results, suggests a role for 
dAlk as a rate-limiting activator of 
functionally important dNf1-regulated 
neuronal RAS/ERK signals.13 The fact 
that attenuation of dAlk signaling rescues 
multiple dNf1 defects raises important 
questions whether NF1-regulated ALK/
RAS/ERK signaling is conserved in 
man, and whether ALK should be further 
investigated as a therapeutic target in 
NF1. Several observations suggest positive 
answers to both questions. Thus, as we 
previously found for dAlk and dNf1,13 
Figure 2. Model of dNf1-regulated systemic growth. Neurofibromin functions in neurons of the 
larval central nervous system to regulate Jeb/dalk-stimulated raS/MeK/erK signaling. In ways 
that remain poorly understood, excessive neuronal raS/MeK/erK signaling leads to synaptic 
architecture or neurotransmission defects, which appear causally linked to the reduced growth 
phenotype. Suggesting a neuroendocrine non-cell-autonomous mechanism, increasing caMp/
pKa signaling in specific segments of the larval brain-associated neuroendocrine ring gland 
suffices to suppress the dNf1 growth defect. In contrast, only widespread neuronal dNf1 expression 
restores mutant growth.
e28341-4 rare Diseases Volume 2 
the expression of Alk and Nf1 in the 
mouse nervous system overlaps to a large 
extent.22,23 Supporting an evolutionary 
conserved functional link between both 
proteins, mutations that activate ALK or 
that block the expression of NF1 have 
both been implicated in neuroblastoma 
tumorigenesis.24,25 Adding to this indirect 
evidence, our recent study found that 
shRNA-mediated suppression of NF1 
expression renders human neuroblastoma 
cells resistant to pharmacological ALK 
inhibition.14 Specifically, we used two 
human neuroblastoma lines harboring 
constitutively active F1174L ALK 
alleles. Both lines are highly sensitive 
to pharmacological inhibition of ALK 
with either NVP-TAE684 or Crizotinib. 
Retroviral shRNA-mediated NF1 
knockdown increased the resistance of 
these cells to both inhibitors, as evidenced 
by continued growth and sustained MEK/
ERK activation. Further, expression 
of activated KRAS, BRAF, or MEK 
transgenes, but not of other Ras effector 
transgenes, conferred similar resistance 
to ALK inhibition.14 Two additional 
observations suggest a potential role for 
ALK in NF1 tumorigenesis. First, we 
found that human ALK is expressed in 
neurofibroma-derived NF1−/− Schwann 
cells, as well as in cells derived from 
malignant NF1 tumors. Second, others 
previously reported that the human ALK 
ligand midkine is aberrantly expressed in 
NF1 deficient murine Schwann cells, and 
acts as a potent mitogen for human NF1 
tumor cells.26 Thus, among the various 
phenotypic suppressors identified in our 
screen, we feel that ALK should with 
highest priority be further investigated as 
a potential therapeutic target in NF1.
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